Galectin Therapeutics Inc. (GALT) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Galectin Therapeutics Inc...

    NASDAQ: GALT · Real-Time Price · USD
    4.29
    -0.26 (-5.71%)
    At close: Sep 29, 2025, 1:10 PM

    Galectin Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 37K 33K 32K 41K
    Gross Profit
    		 -37K -33K -32K -41K
    Operating Income
    		 -42.43M -38.07M -38.35M -30.18M
    Interest Income
    		 338K 230K 52K 3K
    Pretax Income
    		 -47.05M -41.07M -38.78M -30.53M
    Net Income
    		 -47.05M -41.07M -38.78M -30.53M
    Selling & General & Admin
    		 5.86M 5.94M 6.62M 6.36M
    Research & Development
    		 36.57M 32.13M 31.74M 23.82M
    Other Expenses
    		 n/a -0.00 n/a n/a
    Operating Expenses
    		 42.43M 38.04M 38.35M 30.18M
    Interest Expense
    		 5.54M 2.79M 1.03M 489K
    Selling & Marketing Expenses
    		 n/a 44K n/a n/a
    Cost & Expenses
    		 42.43M 38.07M 38.35M 30.18M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 62.31M 60.16M 59.39M 58.53M
    Shares Outstanding (Diluted)
    		 62.31M 60.16M 59.39M 58.53M
    EPS (Basic)
    		 -0.76 -0.74 -0.65 -0.52
    EPS (Diluted)
    		 -0.76 -0.74 -0.65 -0.52
    EBITDA
    		 -41.47M -38.24M -38.27M -30M
    EBIT
    		 -41.51M -38.27M -37.74M -30.18M
    Depreciation & Amortization
    		 37K 33K 32K 41K

    Add to Watchlist